Sputnik Light Covid vaccine gets approval for Phase 3 trials in India

A single-dose COVID-19 vaccine variant of 'Sputnik Light,' Sputnik-V vaccine, was approved by the Indian drug control officer General for studies to check that it gives an immobile immune response similar to that of Russians in trials.

0
Sputnik Light Covid vaccine gets approval for Phase 3 trials in India

A single-dose COVID-19 vaccine variant of ‘Sputnik Light,’ Sputnik-V vaccine, was approved by the Indian drug control officer General for studies to check that it gives an immobile immune response similar to that of Russians in trials.

The Test Condition based on the effectiveness of the vaccination was suggested by a Subject Expert (SEC) conference on 5 August and should be assessed also 42nd, 90th and 180thdays after the second dosage.” Interim analysis can be conducted on day 42 as this data was generated during the Sputnik V trials in India after the first dose, which was stated to be available up to day 21,” reads the minutes of the SEC meeting.

The two-dose version, Sputnik V, was certified by the Drugs Controller General of India earlier in the month of April for emergency use (DCGI).To date, 8-9 lakh doses of Sputnik V have been given in India according to Dr. K Paul, Member (Health) of NITI Aayog. The efficacy of 79 percent was demonstrated by Sputnik Light, the first dosage of the original 2-dose formulation.

Summary
Article Name
Sputnik Light Covid vaccine gets approval for Phase 3 trials in India
Description
A single-dose COVID-19 vaccine variant of 'Sputnik Light,' Sputnik-V vaccine, was approved by the Indian drug control officer General for studies to check that it gives an immobile immune response similar to that of Russians in trials.
Author
Publisher Name
THE POLICY TIMES
Publisher Logo